Frederik Deroose, has more than 25 years of experience in drug research and is part of the drug discovery team at AGILeBiotics. Before joining AGILeBiotics in 2019, Dr. Deroose was Director at Janssen Pharmaceuticals (part of Johnson and Johnson) in the medicinal chemistry team for 18 years where he was a key contributor in numerous discovery programs and an inventor of multiple New Molecular Entities (NMEs) in the fields of Inflammation, Neuroscience and Oncology and Anti-Infectives.

He has experience in anti-infective discovery programs and is currently an active member of the IMI-funded consortium ENABLE (European Gram-Negative Antibacterial Engine) as part of the ‘New Drugs for Bad Bugs’ (ND4BB) program. The ENABLE project is working to advance the development of potential antibiotics against Gram-negative bacteria. He received his Ph.D. in Organic Chemistry, 1995 from University Ghent, Belgium and performed postdoctoral research at the Scripps Research Institute, San Diego on Natural product and medicinal chemistry.

At AGILeBiotics, Dr. Deroose supports the preclinical programs by using his in depth expertise in the coordination of drug discovery programs.